Moneycontrol PRO
you are here: HomeNewsOpinion

Is Glenmark Life Sciences another Divi's in the making?

Glenmark Life Sciences' IPO timing is opportune, but it needs to strike deep relationships with global innovators and attain market leadership in key products

July 22, 2021 / 09:49 AM IST
Is Glenmark Life Sciences another Divi's in the making?

Representative image

Glenmark Pharmaceuticals has chosen an opportune time to launch the initial public offering (IPO) of its subsidiary Glenmark Life Sciences. Primary markets are red hot and the company has encouraging numbers to back its issue. Revenues are up 22.6 percent last fiscal and the company’s profitability is notably better than many of its local peers. Still, prospective investors in its IPO will be keen to know its future potential. Can it replicate the success of Divi's Laboratories, a large active pharmaceutical ingredients (API) manufacturer based out of...

  • PRO Panorama

    Moneycontrol Pro Panorama | Robinhood missed the mark on a bumper listing

    Jul 30, 2021 / 04:26 PM IST

    In today’s edition of Moneycontrol Pro Panorama:  Why Robinhood stumbled, the problem with IMF forecasts, the Immunity Tracker, Tech Mahindra’s growth appeal, Tactical Pick, the Indian startup rage, China pushes back on crypto and more  

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers